Ana Oaknin

Ana Oaknin is a gynecologic oncologist at Vall d'Hebron and ENGOT collaborator who has been a principal investigator on the RUBY trial of dostarlimab plus carboplatin-paclitaxel for endometrial cancer including carcinosarcoma histology. Her work has demonstrated that carcinosarcoma patients included in immunotherapy trials of endometrial cancer can achieve responses when tumors are dMMR or POLE-mutated, and she has contributed to subgroup analyses informing the approval of pembrolizumab and dostarlimab in carcinosarcoma. She co-chairs GEICO Spanish gynecologic oncology group.